In vitro tests on the HT-29-CD133-positive cell line (colon cancer) showed that CD133-targeted Doxil had a significantly higher cellular uptake, binding, and internalization which lowered the inhibitory doxorubicin concentration compared to non-targeted Doxil. The gene discussed is PROM1; the disease is colonic neoplasm.